The Landscape of Transcriptomic Diversity in Oncology

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 30 August 2024 | Viewed by 11278

Special Issue Editors


E-Mail Website
Guest Editor
Graduate School of Agriculture, Osaka Metropolitan University, 1-1 Gakuencho, Naka-ku, Sakai 599-8531, Japan
Interests: thyroid carcinoma; non-coding RNA; transcriptomics; RNA biomarker; molecular diagnosis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Endocrine Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
Interests: thyroid carcinoma; biomarker; molecular diagnosis; ultrasonography

Special Issue Information

Dear Colleagues, 

Recently, the development of transcriptome analyses has been drastically accelerated, which is largely depends on the improved performance of next-generation sequencing. Big data collected from the analyses have not only provided information about aberrant gene expression in various cancer types but also enabled to discover thousands of the novel splice variants of annotated transcripts and unannotated long non-coding RNAs, providing new sources for identification of clinical biomarkers and druggable targets. Especially, cancer-related transcripts have attracted attention because there are still few cancer biomarkers and drugs with satisfactory effectiveness. In this Special Issue category, we highlight the landscape of transcriptomic diversity in oncology

Dr. Osamu Ishibashi
Dr. Tomoo Jikuzono
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transcriptome
  • transcriptomics
  • RNA sequencing
  • next-generation sequencing
  • non-coding RNA
  • splice variant
  • cancer biomarker

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

28 pages, 5675 KiB  
Article
Downregulation of Dystrophin Expression Occurs across Diverse Tumors, Correlates with the Age of Onset, Staging and Reduced Survival of Patients
by Nancy Alnassar, Malgorzata Borczyk, Georgia Tsagkogeorga, Michal Korostynski, Namshik Han and Dariusz C. Górecki
Cancers 2023, 15(5), 1378; https://doi.org/10.3390/cancers15051378 - 21 Feb 2023
Cited by 2 | Viewed by 10628
Abstract
Altered dystrophin expression was found in some tumors and recent studies identified a developmental onset of Duchenne muscular dystrophy (DMD). Given that embryogenesis and carcinogenesis share many mechanisms, we analyzed a broad spectrum of tumors to establish whether dystrophin alteration evokes related outcomes. [...] Read more.
Altered dystrophin expression was found in some tumors and recent studies identified a developmental onset of Duchenne muscular dystrophy (DMD). Given that embryogenesis and carcinogenesis share many mechanisms, we analyzed a broad spectrum of tumors to establish whether dystrophin alteration evokes related outcomes. Transcriptomic, proteomic, and mutation datasets from fifty tumor tissues and matching controls (10,894 samples) and 140 corresponding tumor cell lines were analyzed. Interestingly, dystrophin transcripts and protein expression were found widespread across healthy tissues and at housekeeping gene levels. In 80% of tumors, DMD expression was reduced due to transcriptional downregulation and not somatic mutations. The full-length transcript encoding Dp427 was decreased in 68% of tumors, while Dp71 variants showed variability of expression. Notably, low expression of dystrophins was associated with a more advanced stage, older age of onset, and reduced survival across different tumors. Hierarchical clustering analysis of DMD transcripts distinguished malignant from control tissues. Transcriptomes of primary tumors and tumor cell lines with low DMD expression showed enrichment of specific pathways in the differentially expressed genes. Pathways consistently identified: ECM-receptor interaction, calcium signaling, and PI3K-Akt are also altered in DMD muscle. Therefore, the importance of this largest known gene extends beyond its roles identified in DMD, and certainly into oncology. Full article
(This article belongs to the Special Issue The Landscape of Transcriptomic Diversity in Oncology)
Show Figures

Figure 1

Back to TopTop